trehalose has been researched along with MPTP Neurotoxicity Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akopyan, AA; Dubrovina, NI; Korolenko, TA; Pupyshev, AB; Tenditnik, MV; Tikhonova, MA | 1 |
| Ferguson, SA; Law, CD; Sarkar, S | 1 |
2 other study(ies) available for trehalose and MPTP Neurotoxicity Syndrome
| Article | Year |
|---|---|
Therapeutic activation of autophagy by combined treatment with rapamycin and trehalose in a mouse MPTP-induced model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autophagy; Behavior, Animal; Cognition; Corpus Striatum; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Drug Therapy, Combination; Male; Mice; Mice, Inbred C57BL; Microtubule-Associated Proteins; MPTP Poisoning; Neuroprotective Agents; Neurotoxins; Parkinson Disease; Sirolimus; Substantia Nigra; Trehalose; Tyrosine 3-Monooxygenase | 2019 |
Chronic MPTP treatment produces hyperactivity in male mice which is not alleviated by concurrent trehalose treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Disease Models, Animal; Hyperkinesis; Male; Mice; Mice, Inbred C57BL; Motor Activity; MPTP Poisoning; Neuroprotective Agents; Probenecid; Trehalose | 2015 |